Table 1.
Demographics and clinical features of the study participants
| N = 94 | |
|---|---|
| Age (years) mean ± SD | 58.49 ± 10.96 |
| BMI (kg/m2) mean ± SD | 29.96 ± 5.57 |
| BMI, n (%) | |
| ≥ 25 | 81(86.2) |
| < 25 | 13(13.8) |
| Married, n (%) | 67(71.3) |
| With whom she lived, n (%) | |
| Alone | 14(14.9) |
| Husband | 18(19.1) |
| Children | 13(13.8) |
| Husband&Children | 48(51.1) |
| Parents | 1(1.1) |
| Level of Education, n (%) | |
| İlliterate | 14(14.9) |
| Semiliterate | 11(11.7) |
| Primary school | 33(35.1) |
| High school | 21(22.3) |
| University | 15(16) |
| Economic status, n (%) | |
| High | 5(5.3) |
| Medium | 30(31.9) |
| Low | 59(62.8) |
| Smoker, n (%) | 13(13.8) |
| Hormone theraphy, n (%) | |
| None | 21(22.3) |
| Tamoxifen | 28(29.8) |
| Letrozole | 37(39.4) |
| Anastrazole | 8(8.5) |
| Duration of Lymphedema (months) mean(min–max) | 38.40(1–200) |
| Stages of lymphedema, n (%) | |
| Stage I | 5(5.3) |
| Stage II | 45(47.9) |
| Stage III | 44(46.8) |
| HCFS score, mean ± SD | 47.64 ± 15.54 |
| PSQI Global Score, mean ± SD | 8.21 ± 4.28 |
| LYMQOL- ARM score, mean ± SD | 59.10 ± 17.71 |
| Global health status, mean ± SD (LYMQOL-ARM scale) | 5.13 ± 1.83 |
HCFS, Hirai Cancer Fatigue Scale; PSQI, Pittsburgh Sleep Quality Index; LYMQOL, Lymphedema-specific Quality of Life